Wonder Drug? The GLP-1 Story · Episode 4 of 6 · 21 min
The Mind on GLP-1
Health records from millions of patients suggest people on GLP-1 drugs are diagnosed with Alzheimer's less often. Yet the randomized trials in people already ill, including the large EVOKE trials, did not slow the disease. The episode sits in that gap between hope and proof, asking whether the drugs fail or are tested too late.
Who's who
- Clive BallardLed the ELAD liraglutide-in-Alzheimer's trial
Timeline
- 2020REWIND analysis of dulaglutide shows a modest reduction in cognitive impairment
- October 2024Semaglutide target-trial emulation reports a hazard ratio of 0.33 versus insulin
- November 24, 2025Novo Nordisk announces the EVOKE and EVOKE+ Alzheimer's trials were negative
- December 2025ELAD published in full, confirming its primary endpoint failed
- January 13, 2026FDA moves to remove the suicidal-behavior warning from GLP-1 labels
- April 2026A conference abstract raises a "survival paradox" counter-signal
Still debated
Whether the dementia signal in health records is real or an artifact of confounding is unresolved. It is also unclear whether any benefit is prevention only, whether effects are direct or indirect, and whether the survival paradox means anything.